|Bid||40.50 x 800|
|Ask||40.83 x 800|
|Day's Range||39.60 - 40.61|
|52 Week Range||34.06 - 82.35|
|Beta (3Y Monthly)||1.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2017 - Nov 20, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||81.00|
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, has resumed patient enrollment into its TRANSCEND clinical trial and is nearly 75 percent of the way to its goal of 446 randomized patients. Patient enrollment in TRANSCEND, the pivotal clinical trial for the SurVeil™ drug-coated balloon (DCB), was temporarily paused following the March 15 publication of a Food & Drug Administration (FDA) letter to physicians.
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But when you pick a company that is really flourishing, you can make more than 100%. For exam...
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will make a presentation to the investment community at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, at 1:30 p.m. ET (12:30 p.m. CT). A live audio webcast of the presentation will be available by going to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com, clicking on the webcast link and, on the conference's registration page, completing the required fields to register.
A Food and Drug Administration probe into chemotherapy drug paclitaxel is testing the waters for medical device companies SurModics, Boston Scientific, Medtronic and Becton Dickinson.
Surmodics Inc said in a securities filing Monday that it was working with the Food and Drug Administration to clarify how the agency's Friday warning about paclitaxel-coated balloons and paclitaxel-eluting stents would affect the company's clinical trial evaluating SurVeil, its drug-coated balloon for the treatment of peripheral artery disease. In the Monday filing, Surmodics said it was "currently assessing the impact of the FDA communication on the TRANSCEND clinical trial, its expectations regarding the timing of completion of patient enrollment in the TRANSCEND clinical trial and related regulatory approvals for the SurVeil DCB, and any corresponding effect on its fiscal 2019 financial guidance." The FDA first said in January that it would be evaluating the potential for increased long-term mortality after using paclitaxel-coated balloons and stents. On Friday, the agency said a preliminary analysis of three trials had "identified a potentially concerning signal of increased long-term mortality in study subjects treated with paclitaxel-coated products compared to patients treated with uncoated devices." The FDA's data followed a meta-analysis published in December in the Journal of the American Heart Association showing a possible increase in mortality after two years in patients treated with paclitaxel balloons or stents. Shares of Surmodics have gained 14% in the past three months, while the S&P 500 has gained 10.8%.
Wright Medical's (WMGI) top-line growth in fourth-quarter 2018 can be attributed to solid performance by the Upper and the Lower Extremities segments.
NEW YORK, Feb. 26, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
With regard to its 2019 PBM selling season, CVS Health (CVS) notes that the net benefits from this selling season are expected to be modest on Anthem-related headwinds.
DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.
Surmodics' (SRDX) solid efforts to improve its research and development stature are likely to prove beneficial in the quarters ahead.
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced the appointment of Timothy J. Arens, Vice President of Corporate Development and Strategy, as the company’s new Chief Financial Officer (CFO), effective immediately. Arens was named interim CFO in May 2018 following the departure of Andrew LaFrence. Arens’ corporate development and strategy responsibilities will be absorbed into his CFO role.
Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.